In agreement with that information, our data show that the CIS drug has the main synergism with NCI (Figure 2), and in our model, it was mapped with PDMP (a glucosylceramide synthase inhibitor, Figure 4). The gene discussed is UGCG; the disease is in situ carcinoma.